Tiffany Khong

Dr

19952019
If you made any changes in Pure these will be visible here soon.

Research Output 1995 2019

Filter
Article
2019

DNA-repair gene mutations are highly prevalent in circulating tumour dna from multiple myeloma patients

Mithraprabhu, S., Hocking, J., Ramachandran, M., Choi, K., Klarica, D., Khong, T., Reynolds, J. & Spencer, A., 29 Jun 2019, In : Cancers. 11, 7, 14 p., 917.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients

Mithraprabhu, S., Morley, R., Khong, T., Kalff, A., Bergin, K., Hocking, J., Savvidou, I., Bowen, K. M., Ramachandran, M., Choi, K., Wong, B. K. L., Reynolds, J. & Spencer, A., Aug 2019, In : Leukemia. 33, 8, p. 2022-2033 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)

Kalff, A., Khong, T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R., Wang, M., Couto, S., Ren, Y. & Spencer, A., Jun 2019, (Accepted/In press) In : Leukemia and Lymphoma. 9 p.

Research output: Contribution to journalArticleResearchpeer-review

2017

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

Mithraprabhu, S., Khong, T., Ramachandran, M., Chow, A., Klarica, D., Mai, L., Walsh, S., Broemeling, D., Marziali, A., Wiggin, M., Hocking, J., Kalff, A., Durie, B. & Spencer, A., 1 Aug 2017, In : Leukemia. 31, 8, p. 1695-1705 11 p.

Research output: Contribution to journalArticleResearchpeer-review

β-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma

Savvidou, I., Khong, T., Cuddihy, A., McLean, C., Horrigan, S. & Spencer, A., 1 Sep 2017, In : Molecular Cancer Therapeutics. 16, 9, p. 1765-1778 14 p.

Research output: Contribution to journalArticleResearchpeer-review

2016

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: Pivotal role of MCL1

Gong, J. N., Khong, T., Segal, D., Yao, Y., Riffkin, C. D., Garnier, J. M., Lin Khaw, S., Lessene, G., Spencer, A., Herold, M. J., Roberts, A. W. & Huang, D. C. S., 1 Jan 2016, In : Blood. 128, 14, p. 1834-1844 11 p.

Research output: Contribution to journalArticleResearchpeer-review

2015

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide

Asvadi, P., Cuddihy, A. R., Dunn, R., Jiang, V., Wong, M. X., Jones, D. R., Khong, T. T. F. & Spencer, A., 2015, In : British Journal of Haematology. 169, 3, p. 333 - 343 11 p.

Research output: Contribution to journalArticleResearchpeer-review

2014

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Mithraprabhu, S., Kalff, A., Chow, A., Khong, T. T. F. & Spencer, A., 2014, In : Epigenetics. 9, 11, p. 1511 - 1520 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
2013
2011

CYT997 causes apoptosis in human multiple myeloma

Monaghan, K., Khong, T., Smith, G. & Spencer, A., 2011, In : Investigational New Drugs. 29, 2, p. 232 - 238 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

Khong, T. & Spencer, A., 2011, In : Molecular Cancer Therapeutics. 10, 10, p. 1909 - 1917 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

Monaghan, K., Khong, T., Burns, C. & Spencer, A., 2011, In : Leukemia. 25, 12, p. 1891 - 1899 9 p.

Research output: Contribution to journalArticleOther

2010

Deactylase inhibition in myeloproliferative neoplasms

Mithraprabhu, S., Grigoriadis, G., Khong, T. & Spencer, A., 2010, In : Investigational New Drugs. 28, Suppl 1, p. 50 - 57 8 p.

Research output: Contribution to journalArticleResearchpeer-review

2004

A study of VEGF and its receptors in two rat models of proteinuria

Kanellis, J., Levidiotis, V., Khong, T. T. F., Cox, A. J., Stacker, S. A., Gilbert, R. E., Cooper, M. E. & Power, D. A., 2004, In : Nephron Physiology. 96, 1, p. 26 - 36 11 p.

Research output: Contribution to journalArticleResearchpeer-review

2000

Upregulation of heparin-binding epidermal growth factor-like growth factor and osteopontin in experimental hydronephrosis

Katerelos, M., Kirkl, G., Paizis, K., Khong, T., Kanellis, J. & Power, D., 2000, In : Nephrology. 5, 3, p. 201-208 8 p.

Research output: Contribution to journalArticleResearchpeer-review

1999

Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis

Paizis, K., Kirkland, G., Khong, T., Katerelos, M., Fraser, S., Kanellis, J. & Power, D. A., 1999, In : Kidney International. 55, 6, p. 2310-2321 12 p.

Research output: Contribution to journalArticleResearchpeer-review

1995

Protein synthesis and secretion by cultured retinal pigment epithelia

Jaworowski, A., Fang, Z. P., Khong, T. F. & Augusteyn, R. C., 17 Aug 1995, In : BBA - General Subjects. 1245, 1, p. 121-129 9 p.

Research output: Contribution to journalArticleResearchpeer-review